FDA Approves Amivantamab and Hyaluronidase-lpuj for Subcutaneous Injection By Ogkologos - January 14, 2026 377 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for safety and efficacy is based on the findings from the PALOMA-3 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Equidacent August 6, 2020 What Is Mindfulness and How Can It Help People With Cancer? July 5, 2022 Opinion: ‘Wales needs more than a three-page statement to get cancer... March 22, 2021 FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head... July 18, 2025 Load more HOT NEWS COVID-19 Testing: What you need to know. ESMO Gynaecological Cancers Congress 2022, 17 – 18 June 2022 Valencia,... Changes to chromosomes impact how children’s brain tumours respond to treatment A tribute to Dame Valerie Beral
